Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus
ConclusionInsulin detemir provides similar glycemic control with glargine, but, approximately 27% higher mean basal and 19% higher mean total insulin doses with two‐fold more twice‐daily basal insulin injection requirement. (Source: Pediatric Diabetes)
Source: Pediatric Diabetes - June 1, 2014 Category: Endocrinology Authors: Saygın Abalı, Serap Turan, Zeynep Atay, Tülay Güran, Belma Haliloğlu, Abdullah Bereket Tags: Original Article Source Type: research
Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice
Conclusions
NPH, IG, ID and PM were found to be equally effective in lowering HbA1c in insulin-naïve patients with type 2 diabetes in routine clinical care in Sweden. The effects on weight, dose and treatment persistence support the recommendation of NPH or IG as first and second choices in this group of patients requiring initiation of insulin treatment. (Source: Diabetes Therapy)
Source: Diabetes Therapy - June 1, 2014 Category: Endocrinology Source Type: research
Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs.
CONCLUSIONS: This study showed contrasting clinical and economic outcomes when patients with T2DM switched basal insulin analogs, with worse outcomes observed for patients switching from insulin glargine to insulin detemir and improved outcomes when switching from insulin detemir to insulin glargine. Further investigation into the therapeutic interchangeability of insulin glargine and insulin detemir in the real-world setting is needed.
PMID: 24831915 [PubMed - as supplied by publisher] (Source: Advances in Therapy)
Source: Advances in Therapy - May 16, 2014 Category: Drugs & Pharmacology Authors: Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J Tags: Adv Ther Source Type: research
Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26‐week randomized, open‐label, treat‐to‐target non‐inferiority trial
ConclusionIDeg administered OD in basal–bolus therapy effectively improved long‐term glycaemic control in participants with T1DM with a lower risk of nocturnal confirmed hypoglycaemia than IDet. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - May 8, 2014 Category: Endocrinology Authors: M. J. Davies, J. L. Gross, Y. Ono, T. Sasaki, G. Bantwal, M. A. Gall, M. Niemeyer, H. Seino, Tags: ORIGINAL ARTICLE Source Type: research
Efficacy and safety of insulin degludec given as part of basal − bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26‐week randomised, open‐label, treat‐to‐target non‐inferiority trial
ConclusionIDeg administered OD in basal–bolus therapy effectively improved long‐term glycaemic control in participants with T1DM with a lower risk of nocturnal confirmed hypoglycaemia than IDet. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - April 7, 2014 Category: Endocrinology Authors: M.J. Davies, J.L. Gross, Y. Ono, T. Sasaki, G. Bantwal, M.A. Gall, M. Niemeyer, H. Seino, Tags: ORIGINAL PAPER Source Type: research
Efficacy and safety of insulin degludec given as part of basal - bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomised, open-label, treat-to-target non-inferiority trial.
CONCLUSION: IDeg administered OD in basal-bolus therapy effectively improved long-term glycaemic control in participants with T1DM with a lower risk of nocturnal confirmed hypoglycaemia than IDet.
PMID: 24702700 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - April 7, 2014 Category: Endocrinology Authors: Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, Niemeyer M, Seino H Tags: Diabetes Obes Metab Source Type: research
Glycemic Variability in Patients With Early Type 2 Diabetes: The Impact of Improvement in β-Cell Function.
CONCLUSIONSIn early T2DM, glycemic variability is a modifiable parameter that can be reduced by improving β-cell function with short-term IIT.
PMID: 24550219 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - February 18, 2014 Category: Endocrinology Authors: Kramer CK, Choi H, Zinman B, Retnakaran R Tags: Diabetes Care Source Type: research
Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center
Conclusion: Once-daily use of insulin detemir up to 0.4U/kg was found to have similar efficacy and safety as twice-daily use. Twice dose use of insulin did not provide a prominent glycemic control advantage on 1.5-fold higher use of insulin. (Source: Primary Care Diabetes)
Source: Primary Care Diabetes - February 11, 2014 Category: Primary Care Authors: Soner Cander, Oguzhan Sitki Dizdar, Ozen Oz Gul, Metin Guclu, Oguz Kaan Unal, Ercan Tuncel, Erdinc Erturk, Sazi Imamoglu, Canan Ersoy Tags: Original Research Source Type: research
Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center
To compare once- versus twice-daily insulin detemir added on OADS therapy in insulin-naive type 2 diabetes patients in terms of efficacy and safety. (Source: Primary Care Diabetes)
Source: Primary Care Diabetes - February 11, 2014 Category: Primary Care Authors: Soner Cander, Oguzhan Sitki Dizdar, Ozen Oz Gul, Metin Guclu, Oguz Kaan Unal, Ercan Tuncel, Erdinc Erturk, Sazi Imamoglu, Canan Ersoy Source Type: research
Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus.
CONCLUSION: The similar pharmacokinetic and pharmacodynamic responses to IDeg in 3 racial/ethnic groups of patients with type 2 diabetes mellitus suggest that the flat, stable, and ultralong pharmacokinetic and pharmacodynamic profiles of IDeg are preserved irrespective of race/ethnicity. Although insulin doses must be adjusted on an individual basis, similar pharmacokinetic and pharmacodynamic responses to IDeg are observed in patients with differing race/ethnicity.
PMID: 24508419 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - February 5, 2014 Category: Drugs & Pharmacology Authors: Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H Tags: Clin Ther Source Type: research
Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice
Conclusions: Findings from the UK cohort of SOLVE show that it is possible to improve glycaemic control and reduce HbA1c in patients previously uncontrolled with oral antidiabetic drug therapy, in a primary setting, despite clinical inertia. (Source: Primary Care Diabetes)
Source: Primary Care Diabetes - December 30, 2013 Category: Primary Care Authors: Kamlesh Khunti, Jiten Vora, Melanie Davies Tags: Original Research Source Type: research
Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.
CONCLUSIONS: Findings from the UK cohort of SOLVE show that it is possible to improve glycaemic control and reduce HbA1c in patients previously uncontrolled with oral antidiabetic drug therapy, in a primary setting, despite clinical inertia.
PMID: 24378771 [PubMed - as supplied by publisher] (Source: Primary Care)
Source: Primary Care - December 27, 2013 Category: Primary Care Authors: Khunti K, Vora J, Davies M Tags: Prim Care Diabetes Source Type: research
Daily insulin doses and injection frequencies of Neutral Protamine Hagedorn (NPH) insulin, insulin detemir and glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV‐Wiss database
ConclusionsIn a " real‐world" ‐setting, the injection frequencies and doses of basal and total insulin per day are lowest with the use of insulin glargine compared to NPH‐insulin or insulin detemir at similar glycaemic control and rates of severe hypoglycemia. This article is protected by copyright. All rights reserved. (Source: Diabetes/Metabolism Research and Reviews)
Source: Diabetes/Metabolism Research and Reviews - December 3, 2013 Category: Endocrinology Authors: K. Laubner, K. Molz, W. Kerner, W. Karges, W. Lang, A. Dapp, M. Schütt, F. Best, J. Seufert, R. W. Holl Tags: Research Article Source Type: research
Effect of once‐daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes
In this study, the discontinuation of specific classes of OAD appeared to be more closely associated with weight and history of hypoglycaemia, rather than the degree of glycaemic control. Improvements in glycaemic contol were smaller in patients discontinuing OADs at the time of insulin initiation, and may be associated with insufficient insulin titration. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - December 1, 2013 Category: Drugs & Pharmacology Authors: J. Vora, S. Caputo, T. Damci, D. Orozco‐Beltran, C. Pan, A. L. Svendsen, K. S. Sølje, K. Khunti, Tags: Original Article Source Type: research
Determinants of reversibility of {beta}-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes
In conclusion, decline in HOMA-IR may be a key determinant of improvement of β-cell function in response to short-term IIT, suggesting a fundamental contribution of insulin resistance to the reversible component of β-cell dysfunction in early T2DM. (Source: AJP: Endocrinology and Metabolism)
Source: AJP: Endocrinology and Metabolism - December 1, 2013 Category: Endocrinology Authors: Kramer, C. K., Choi, H., Zinman, B., Retnakaran, R. Tags: Articles Source Type: research
